Zeiss launch new solution updates

Article

Carl Zeiss Meditec presented its expanded offering of ophthalmic solutions at this year's WOC 2010 in Berlin.

Carl Zeiss Meditec presented its expanded offering of ophthalmic solutions at this year's WOC 2010 in Berlin.

Amongst its offerings was the IOLMaster 500 which it claims is the fastest way of calculating the right IOL for every patient. It is part of the ZEISS Toric Solution and, via the FORUM platform, is an integral component of the ZEISS Ophthalmic Data Management Solution, a platform for the management of patient, diagnostic and OR data, for a paperless workflow in the doctor's practice and operating room.

The bitoric MICS intraocular lenses are a new standard range (lenses to +4.0 D cyl and 16-24 D sph) The lenses can be calculated quickly and simply using the Z CALC online calculator.

The AT LISA toric 909MV belongs to the ZEISS IOL family featuring violet filters. Besides UV protection these IOLS offer protection from the potentially more dangerous violet light spectrum. At the same time they transmit blue light, which plays an important role in regulation of the circadian rhythm, without impairing visual quality.

In the OVD Portfolio are the visco-elastic substances used for cataract treatment to enhance visibility of the operation area during the procedure and protect the corneal endothelium.

OPMI Lumera 700 is a surgical microscope which combines basic configuration with extensive options for surgery in the anterior and posterior ocular segments. The new RESIGHT 700 fundus viewing system and innovative Stereo Coaxial Illumination (SCI) illumination technology, allows the doctor to see the patient's eye with detail and brilliance.

Dr Ludwin Monz, President and CEO of Carl Zeiss Meditec AG said: “We have developed these innovations in close dialogue with our customers and we remain on course to further success as a solution provider for ophthalmology and therefore make a contribution to the more effective and efficient treatment of diseases.”

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.